

Luis F C Ensina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1750063/publications.pdf>

Version: 2024-02-01

79
papers

3,547
citations

361045

20
h-index

143772

57
g-index

82
all docs

82
docs citations

82
times ranked

2911
citing authors

#	ARTICLE	IF	CITATIONS
1	The international EAACI/GA ² LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	2.7	392
2	Prevalence, Management, and Anaphylaxis Risk of Cold Urticaria: A Systematic Review and Meta-Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 586-596.e4.	2.0	11
3	Risk factors for systemic reactions in typical cold urticaria: Results from the COLDA ² study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2185-2199.	2.7	20
4	Increased prevalence of autoimmune diseases in children with chronic spontaneous urticaria. <i>Pediatric Allergy and Immunology</i> , 2022, 33, e13736.	1.1	3
5	Adrenaline autoinjector is underprescribed in typical cold urticaria patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2224-2229.	2.7	4
6	Cold urticaria in a pediatric cohort: Clinical characteristics, management, and natural history. <i>Pediatric Allergy and Immunology</i> , 2022, 33, e13751.	1.1	4
7	Desensitization to drugs in children. <i>Allergologia Et Immunopathologia</i> , 2022, 50, 48-57.	1.0	5
8	Validation of UAS7 among children with chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1927-1929.e1.	2.0	9
9	Acute Urticaria and Anaphylaxis: Differences and Similarities in Clinical Management. <i>Frontiers in Allergy</i> , 2022, 3, .	1.2	5
10	Adrenaline autoinjector is under-prescribed in typical cold urticaria patients living in tropical climate countries. <i>Qatar Medical Journal</i> , 2022, 2022, .	0.2	0
11	Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, , .	0.1	0
12	Urticaria and angioedema in children and adolescents: diagnostic challenge. <i>Allergologia Et Immunopathologia</i> , 2022, 50, 17-29.	1.0	2
13	Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement. <i>World Allergy Organization Journal</i> , 2022, 15, 100640.	1.6	18
14	Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2021, 31, 322-331.	0.6	6
15	The Panorama of Primary Angioedema in the Brazilian Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2293-2304.e5.	2.0	10
16	The global impact of the COVID ¹⁹ pandemic on the management and course of chronic urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 816-830.	2.7	58
17	The global burden of chronic urticaria for the patient and society*. <i>British Journal of Dermatology</i> , 2021, 184, 226-236.	1.4	150
18	Biomarkers associated with chronic spontaneous urticaria severity in children. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, AB24.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Clinical Characteristics, Management, and Natural History of Chronic Inducible Urticaria in a Pediatric Cohort. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 757-764.	0.9	9
20	Effects of pregnancy on chronic urticaria: Results of the PREG–UCARE study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3133-3144.	2.7	15
21	How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. <i>World Allergy Organization Journal</i> , 2021, 14, 100542.	1.6	11
22	Anaphylaxis to vaccination and polyethylene glycol: a perspective from the European Anaphylaxis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e659-e662.	1.3	6
23	Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2186-2194.	2.0	7
24	Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals. <i>Anais Brasileiros De Dermatologia</i> , 2021, 96, 497-499.	0.5	2
25	The Challenges in the Follow-Up and Treatment of Brazilian Children with Hereditary Angioedema. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 585-591.	0.9	10
26	Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. <i>Clinical and Translational Allergy</i> , 2021, 11, e12089.	1.4	9
27	Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 901-910.	2.7	10
28	Drug-induced anaphylaxis, elicitors, risk factors, and management in Latin America. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1403-1405.e1.	2.0	5
29	H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 145-147.	0.6	5
30	Risk Factors and Characteristics of Biphasic Anaphylaxis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3388-3395.e6.	2.0	35
31	Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. <i>World Allergy Organization Journal</i> , 2020, 13, 100460.	1.6	30
32	Vitamin-Induced Anaphylaxis. <i>Current Treatment Options in Allergy</i> , 2020, 7, 84-92.	0.9	0
33	Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	2.7	29
34	The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. <i>World Allergy Organization Journal</i> , 2020, 13, 100475.	1.6	13
35	Systematic review about 10 interventions in dermatitis. A document from the Latin American Society of Allergy, Asthma, and Immunology. <i>Revista Alergia Mexico</i> , 2020, 66, 426-455.	0.9	5
36	Angioedema-Induced by Nonsteroidal Anti-inflammatory Drugs: A Genotype-Phenotype Correlation in A Brazilian Population. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 305-307.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organization Journal, 2019, 12, 100011.	1.6	7
38	Rituximab desensitization protocol in a child with secondary lymphoproliferative disease. Annals of Allergy, Asthma and Immunology, 2019, 123, 526.	0.5	3
39	Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. Allergologia Et Immunopathologia, 2019, 47, 515-522.	1.0	19
40	Advances in the pathogenesis representing definite outcomes in chronic urticaria. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 193-197.	1.1	16
41	Controversies in Allergy: Is Skin Testing Required Prior to Drug Challenges?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 412-417.	2.0	16
42	Drug-induced urticaria (DIU) and angioedema in Latin American Countries. Journal of Allergy and Clinical Immunology, 2018, 141, AB48.	1.5	0
43	The EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1393-1414.	2.7	1,008
44	Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organization Journal, 2018, 11, 32.	1.6	30
45	Comments on Balp etÂal. Pediatric Allergy and Immunology, 2018, 29, 669-670.	1.1	4
46	Update on Omalizumab for Urticaria: Whatâ€™s New in the Literature from Mechanisms to Clinic. Current Allergy and Asthma Reports, 2018, 18, 33.	2.4	27
47	The Burden of Chronic Urticaria from Brazilian Patientsâ€™ Perspective. Dermatology and Therapy, 2017, 7, 535-545.	1.4	34
48	Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial. Brazilian Journal of Otorhinolaryngology, 2017, 83, 633-639.	0.4	7
49	Omalizumab as Third-Line Therapy for Urticaria During Pregnancy. Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 326-327.	0.6	17
50	Drug-Induced Anaphylaxis: Clinical Scope, Management, and Prevention. Current Treatment Options in Allergy, 2016, 3, 243-252.	0.9	2
51	Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience. International Archives of Allergy and Immunology, 2016, 169, 121-124.	0.9	27
52	Registries as useful tools in characterization of allergic manifestations. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 250-256.	1.1	8
53	Diagnosis and management of infusion-related hypersensitivity reactions to enzyme replacement therapy for lysosomal diseases: The role of desensitization. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 354-356.	2.0	13
54	Hypersensitivity to non-steroidal anti-inflammatory drugs in pediatric patients. World Allergy Organization Journal, 2015, 8, A120.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Chronic urticaria: the first visit in a specialized unit. World Allergy Organization Journal, 2015, 8, A125.	1.6	1
56	Beta-lactam hypersensitivity: not always what it seems. World Allergy Organization Journal, 2015, 8, A168.	1.6	0
57	Post exposition to etoricoxib in patients with negative oral drug provocation tests. World Allergy Organization Journal, 2015, 8, A186.	1.6	1
58	The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Przegląd Dermatologiczny, 2015, 2, 155-179.	0.0	11
59	Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience. Annals of Allergy, Asthma and Immunology, 2015, 115, 536.	0.5	10
60	Drug-Induced Anaphylaxis in Latin American Countries. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 780-788.	2.0	64
61	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. Alergologia Polska - Polish Journal of Allergology, 2015, 2, T1-T23.	0.0	0
62	Laronidase hypersensitivity and desensitization in type <sc>l</sc> mucopolysaccharidosis: a case report. Pediatric Allergy and Immunology, 2014, 25, 498-499.	1.1	19
63	The <sc>EAACI</sc>/<sc>GA</sc>²/<sc>LEN</sc>/<sc>EDF</sc>/<sc>WAO</sc> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 868-887.	2.7	912
64	Drug-induced anaphylaxis in children: Nonsteroidal anti-inflammatory drugs and drug provocation test. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 825.	2.0	21
65	Methods report on the development of the 2013 revision and update of the <sc>EAACI</sc>/<sc>GA</sc>²/<sc>LEN</sc>/<sc>EDF</sc>/<sc>WAO</sc> guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, e1-29.	2.7	75
66	Multinational experience with hypersensitivity drug reactions in Latin America. Annals of Allergy, Asthma and Immunology, 2014, 113, 282-289.	0.5	42
67	Drug hypersensitivity in children in Brazil. Clinical and Translational Allergy, 2014, 4, P145.	1.4	0
68	A Survey On Drug Reactions in Latin America. Journal of Allergy and Clinical Immunology, 2013, 131, AB172.	1.5	0
69	Management of Adverse Drug Reactions with Suspected Immune Mechanisms in Latin America. Journal of Allergy and Clinical Immunology, 2013, 131, AB172.	1.5	0
70	Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organization Journal, 2013, 6, 18.	1.6	55
71	375â€ŒNon-steroidal Anti-inflammatory Drugs Hypersensitivity. World Allergy Organization Journal, 2012, 5, S120.	1.6	0
72	66â€ŒDrug Reaction with Eosinophilia and Systemic Symptoms (Dress). World Allergy Organization Journal, 2012, 5, S22.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Anaphylaxis related to Laronidase: Case report. Journal of Allergy and Clinical Immunology, 2012, 129, AB185.	1.5	0
74	Outcomes and safety of drug provocation tests. Allergy and Asthma Proceedings, 2011, 32, 301-306.	1.0	26
75	Drug hypersensitivity in students from São Paulo, Brazil. Clinics, 2010, 65, 1009-1011.	0.6	9
76	Epileptic seizure after treatment with thiocolchicoside. Therapeutics and Clinical Risk Management, 2009, 5, 635.	0.9	10
77	Ketoconazole Allergy. Clinics, 2009, 64, 373-374.	0.6	3
78	Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell?autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunology, Immunotherapy, 2005, 54, 61-66.	2.0	58
79	Dendritic cell?tumor cell hybrid vaccination for metastatic cancer. Cancer Immunology, Immunotherapy, 2004, 53, 1111-1118.	2.0	85